{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:49:13Z","timestamp":1783774153896,"version":"3.55.0"},"reference-count":31,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2018,7,26]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the safety of triple antiplatelet therapy (TAT) with cilostazol in patients undergoing stenting for extracranial and\/or intracranial artery stenosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospectively collected database was reviewed to identify patients who underwent stenting for extracranial and\/or intracranial artery stenosis and showed resistance to aspirin and\/or clopidogrel as assessed by pre-stenting thromboelastography (TEG) testing. Patients were assigned to a TAT group and a dual antiplatelet therapy (DAT) group. Major complications were defined as thromboembolic events (transient ischemic attack (TIA), ischemic stroke, and stent thrombosis) or major bleeding events within 30 days, and minor complications were defined as extracranial bleeding that did not require vascular surgery or transfusion within 30 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 183 patients were identified. The incidence of major complications was significantly lower in the TAT group than in the DAT group (TAT group vs. DAT group, 1\/110 vs. 6\/73; P=0.017). TIAs occurred in four patients, with one in the TAT group and three in the DAT group (1\/110 vs. 3\/73; P=0.303). Ischemic strokes occurred in three patients in the DAT group (TAT group vs. DAT group, P=0.062). No major bleeding events or stent thrombosis was recorded in either group. Two patients (one in each group) experienced minor complications that resolved without additional treatment (1\/110 vs. 1\/73; P&gt;0.999).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and\/or intracranial artery stenosis. By employing TAT under TEG guidance, favorable outcomes can be achieved in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/neurintsurg-2018-013987","type":"journal-article","created":{"date-parts":[[2018,8,12]],"date-time":"2018-08-12T12:19:27Z","timestamp":1534076367000},"page":"352-356","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease"],"prefix":"10.1136","volume":"11","author":[{"given":"Zhonghua","family":"Wu","sequence":"first","affiliation":[{"name":"General Hospital of the PLA Rocket Force, The Teaching Hospital of Soochow University, Suzhou, China"},{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"},{"name":"Department of Neurosurgery, The Sixth People\u2019s Hospital of Nantong, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao-Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancheng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jian","family":"Jiang","sequence":"additional","affiliation":[{"name":"General Hospital of the PLA Rocket Force, The Teaching Hospital of Soochow University, Suzhou, China"},{"name":"Department of Vascular Neurosurgery, New Era Stroke Care and Research Institute, General Hospital of the PLA Rocket Force, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,12]]},"reference":[{"key":"2025092913054069000_11.4.352.1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.4.532"},{"key":"2025092913054069000_11.4.352.2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2431060139"},{"key":"2025092913054069000_11.4.352.3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamaneurol.2015.0654","article-title":"Standard vs modified antiplatelet preparation for preventing thromboembolic events in patients with high on-treatment platelet reactivity undergoing coil embolization for an unruptured intracranial aneurysm: a randomized clinical trial","volume":"72","author":"Hwang","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025092913054069000_11.4.352.4","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2014-011357"},{"key":"2025092913054069000_11.4.352.5","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3405"},{"key":"2025092913054069000_11.4.352.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.034"},{"key":"2025092913054069000_11.4.352.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"2025092913054069000_11.4.352.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.048"},{"key":"2025092913054069000_11.4.352.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.822791"},{"key":"2025092913054069000_11.4.352.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.05.034"},{"key":"2025092913054069000_11.4.352.11","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-012-0788-5"},{"key":"2025092913054069000_11.4.352.12","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000128018.57526.3a"},{"key":"2025092913054069000_11.4.352.13","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2015-011687"},{"key":"2025092913054069000_11.4.352.14","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.015538"},{"key":"2025092913054069000_11.4.352.15","doi-asserted-by":"crossref","unstructured":"Shim EJ , Ryu CW , Park S , et al . Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis. J Neurointerv Surg 2018:Published Online First: 19 January 2018.\u00a0 10.1136\/neurintsurg-2017-013632:neurintsurg-2017-013632.doi:10.1136\/neurintsurg-2017-013632","DOI":"10.1136\/neurintsurg-2017-013632"},{"key":"2025092913054069000_11.4.352.16","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2013-011023"},{"key":"2025092913054069000_11.4.352.17","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-13-0594"},{"key":"2025092913054069000_11.4.352.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.290"},{"key":"2025092913054069000_11.4.352.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61088-4"},{"key":"2025092913054069000_11.4.352.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.18.2018"},{"key":"2025092913054069000_11.4.352.21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002490","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and patient outcomes (PLATO) trial","volume":"4","author":"Andell","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2025092913054069000_11.4.352.22","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2012-010334"},{"key":"2025092913054069000_11.4.352.23","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2009.39.11.462"},{"key":"2025092913054069000_11.4.352.24","doi-asserted-by":"publisher","DOI":"10.1159\/000353674"},{"key":"2025092913054069000_11.4.352.25","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S119616","article-title":"The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients","volume":"10","author":"Fan","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2025092913054069000_11.4.352.26","doi-asserted-by":"publisher","DOI":"10.1177\/0003319712474113"},{"key":"2025092913054069000_11.4.352.27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/01616412.2017.1301042","article-title":"Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting","volume":"39","author":"Nakagawa","year":"2017","journal-title":"Neurol Res"},{"key":"2025092913054069000_11.4.352.28","doi-asserted-by":"publisher","DOI":"10.1159\/000360811"},{"key":"2025092913054069000_11.4.352.29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jphs.2016.04.023","article-title":"Protective effects of cilostazol against hemorrhagic stroke: current and future perspectives","volume":"131","author":"Takagi","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"2025092913054069000_11.4.352.30","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.661173"},{"key":"2025092913054069000_11.4.352.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030190"}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/neurintsurg-2018-013987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:05:50Z","timestamp":1759176350000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/neurintsurg-2018-013987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,12]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,3,19]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/neurintsurg-2018-013987"],"URL":"https:\/\/doi.org\/10.1136\/neurintsurg-2018-013987","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"value":"1759-8478","type":"print"},{"value":"1759-8486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,12]]}}}